Loading..

DermTech, Inc. (DMTK) Report Analysis

Corporate Events

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Small Cap Comp Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000 Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000 Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Small Cap Completeness Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2500 Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000E Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000E Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Microcap Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2500 Growth Index

Positive

DermTech, Inc.(NasdaqCM:DMTK) added to Russell ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) added to Russell Microcap Value Index

Positive

DermTech, Inc.(NasdaqCM:DMTK) added to Russell ...

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) added to Russell 3000E Value Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from S&P ...

2022-06-11 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from S&P Biotechnology Select Industry Index

Neutral

DermTech, Inc. Presents at William Blair’s 42nd...

2022-06-03 14:09:00

DermTech, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 03:00 PM. Venue: Loews Chicago Hotel, Chicago...

Positive

DermTech, Inc. Presents New Research Differenti...

2022-05-18 20:30:00

DermTech, Inc. announced its presentation at the Society for Investigative Dermatology’s (SID) annual meeting, held from May 18-21, 2022 in Po...

Neutral

DermTech, Inc. Affirms Revenue Guidance for the...

2022-05-03 20:05:00

DermTech, Inc. affirms revenue guidance for the full-year 2022. The company affirmed its full-year 2022 outlook for assay revenue between $22 ...

Positive

DermTech, Inc. Announces Publication of New GvH...

2022-04-28 20:30:00

DermTech, Inc. announced the publication of “Noninvasive Genomic Characterization of Patients with Nonsclerotic and Superficially Sclerotic Ch...

Positive

DermTech, Inc. Expands Telehealth Application, ...

2022-04-26 20:30:00

DermTech, Inc. announced the expansion of access to its telehealth application, DermTech Connect, from eight states to 44 states, encompassing...

Neutral

DermTech, Inc. - Shareholder/Analyst Call

2022-04-14 20:06:00

Annual General Meeting

Neutral

DermTech, Inc., Annual General Meeting, May 26, 2022

2022-04-14 20:06:00

DermTech, Inc., Annual General Meeting, May 26, 2022, at 13:30 Pacific Standard Time. Agenda: To elect two (2) Class I directors to serve thre...

Neutral

DermTech, Inc. to Report Q1, 2022 Results on Ma...

2022-04-14 20:01:00

DermTech, Inc. announced that they will report Q1, 2022 results on May 03, 2022

Neutral

DermTech, Inc., Q1 2022 Earnings Call, May 03, 2022

2022-04-14 20:01:00

DermTech, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

DermTech, Inc. Presents at 11th SVB Leerink Ann...

2022-01-31 21:01:00

DermTech, Inc. Presents at 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb-14-2022 . Venue: New York, New York, United States.

Neutral

William Blair & Company, L.L.C., William Blair’...

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chi...

Neutral

BioIQ, Inc. and DermTech, Inc. Enter into an Ag...

2021-12-15 17:23:00

BioIQ, Inc. and DermTech, Inc. announced an agreement to bring increased patient access to precision genomics. The DermTech Melanoma Test is n...

Positive

DermTech Unveils DermTech Stratum

2021-11-29 21:30:00

DermTech, Inc. announced the expansion and branding of its translational medicine service offering, DermTech Stratum, which utilizes DermTech’...

Neutral

DermTech, Inc. Presents at 5th Annual Dermatolo...

2021-11-16 11:51:00

DermTech, Inc. Presents at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Nov-16-2021 . Speakers: Michael Howe...

Neutral

Hanson Wade Limited, 5th Annual Dermatology Dru...

2021-11-15 12:30:00

Hanson Wade Limited, 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Nov 16, 2021 through Nov 18, 2021.

Negative

DermTech, Inc. Revised Assay Revenue Guidance f...

2021-11-09 21:01:00

DermTech, Inc. announced that due to unforeseen impacts from the Delta variant and hurricane Ida, Management revised its estimated full year 2...

Neutral

DermTech, Inc. and DermatologistOnCall Enter Ag...

2021-11-08 21:50:00

DermTech, Inc. and DermatologistOnCall announced an agreement to make the DermTech Melanoma Test available through DermatologistOnCall’s telem...

Neutral

DermTech, Inc. Presents at 15th Annual Canaccor...

2021-11-02 20:41:00

DermTech, Inc. Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 01:30 PM.

Neutral

DermTech, Inc. Presents at 12th Annual Craig-Ha...

2021-11-02 20:01:00

DermTech, Inc. Presents at 12th Annual Craig-Hallum Alpha Select Conference 2021, Nov-16-2021 .

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

DermTech, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-26 20:01:00

DermTech, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

DermTech, Inc. to Report Q3, 2021 Results on No...

2021-10-26 20:01:00

DermTech, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

DermTech, Inc. Presents at MedTech Innovation F...

2021-10-25 13:48:00

DermTech, Inc. Presents at MedTech Innovation Forum 2021, Oct-28-2021 11:20 AM. Venue: AV Irvine, Irvine, California, United States. Speakers:...

Neutral

OCTANe LLC, MedTech Innovation Forum 2021, Oct ...

2021-10-25 11:30:00

OCTANe LLC, MedTech Innovation Forum 2021, Oct 28, 2021 through Oct 29, 2021. Venue: AV Irvine, Irvine, California, United States.

Neutral

Canaccord Genuity LLC, 15th Annual Canaccord Ge...

2021-10-14 22:02:00

Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021.

Negative

DermTech Announces Appointment of Nathalie Gers...

2021-10-04 20:01:00

DermTech, Inc. announced the appointment of Nathalie Gerschtein Keraudy, President of the Consumer Products Division of L’Oréal, to its board ...

Positive

DermTech, Inc Leases Approximately 96,000 Squar...

2021-09-22 15:30:00

Cushman & Wakefield announced that DermTech, Inc. has leased approximately 96,000 square feet of Class A space at the Del Mar Corporate Centre...

Neutral

DermTech, Inc. Presents at Oppenheimer Fall Hea...

2021-09-08 20:01:00

DermTech, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-22-2021 04:35 PM.

Neutral

Craig-Hallum Capital Group LLC, 12th Annual Cra...

2021-09-08 08:33:00

Craig-Hallum Capital Group LLC, 12th Annual Craig-Hallum Alpha Select Conference 2021, Nov 16, 2021.

Neutral

DermTech, Inc. Presents at 2021 Florida Associa...

2021-09-05 04:14:00

DermTech, Inc. Presents at 2021 Florida Association of Health Plans Annual Conference, Nov-14-2021 .

Neutral

Florida Association of Health Plans, 2021 Flori...

2021-09-02 21:59:00

Florida Association of Health Plans, 2021 Florida Association of Health Plans Annual Conference, Nov 14, 2021 through Nov 16, 2021.

Neutral

DermTech, Inc. Provides Financial Guidance for ...

2021-08-04 20:01:00

DermTech, Inc. provided financial guidance for the full year 2021. Management estimates that full year 2021 assay revenue will be between $11....

Neutral

DermTech, Inc. Presents at Lake Street Capital ...

2021-07-31 04:07:00

DermTech, Inc. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021 .

Neutral

Lake Street Capital Markets, LLC, Lake Street C...

2021-07-30 21:59:00

Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021.

Negative

DermTech Names Monica Tellado to Its Board of Directors

2021-07-24 15:59:00

DermTech reported the appointment of Monica Tellado, Senior Vice President, Finance at Gilead Sciences to its Board of Directors. Tellado's ex...

Neutral

DermTech, Inc. to Report Q2, 2021 Results on Au...

2021-07-21 20:30:00

DermTech, Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

DermTech, Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-21 20:30:00

DermTech, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Positive

DermTech, Inc. Announces Expansion Plans to Sup...

2021-07-21 20:05:00

DermTech, Inc. announced expansion plans to support the Company’s continued growth in San Diego, with the lease of a building owned by Kilroy ...

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Health...

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Neutral

Dermtech, Inc., Enters into an Office Lease, or...

2021-07-07 21:01:00

On July 1, 2021, DermTech, Inc., or the Company, entered into an Office Lease, or the Lease, with Kilroy Realty, L.P., or the Landlord, with r...

Negative

Scott Pancoast Resigns from the Board of Direct...

2021-07-02 21:01:00

On June 30, 2021, DermTech, Inc. and Scott Pancoast, a former director of the Company, voluntarily resigned from the Board of Directors of the...

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Small Cap Comp Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000 Growth Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000 Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000 Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000 Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Small Cap Completeness Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Small Cap Completeness Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Growth Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2500 Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2500 Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000E Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000E Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000E Growth Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 3000E Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Microcap Growth Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell Microcap Growth Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2500 Growth Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2500 Growth Index

Positive

DermTech, Inc.(NasdaqCM:DMTK) added to Russell Microcap Value Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) added to Russell Microcap Value Index

Positive

DermTech, Inc.(NasdaqCM:DMTK) added to Russell 3000E Value Index

2022-06-24 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) added to Russell 3000E Value Index

Negative

DermTech, Inc.(NasdaqCM:DMTK) dropped from S&P Biotechnology Select Industry Index

2022-06-11 00:00:00

DermTech, Inc.(NasdaqCM:DMTK) dropped from S&P Biotechnology Select Industry Index

Neutral

DermTech, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 03:00 PM

2022-06-03 14:09:00

DermTech, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 03:00 PM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Positive

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

2022-05-18 20:30:00

DermTech, Inc. announced its presentation at the Society for Investigative Dermatology’s (SID) annual meeting, held from May 18-21, 2022 in Portland, OR. DermTech collected epidermal skin samples from patients with moderate to severe atopic dermatitis and psoriasis for this research study. RNA was isolated and analyzed for expression of specific biomarkers associated with atopic dermatitis and psoriasis, with IL-13, CCL17/TARC, CCL26/Eotaxin-3, IL-17A, CXCL9, CXCL 10, and NOS2 exhibiting the greatest differences. Using a machine-learning approach, DermTech identified a unique ratio that stratified patients into atopic dermatitis versus psoriasis. Among the most diagnosed inflammatory skin conditions, atopic dermatitis and psoriasis affect up to 10% and 3% of the U.S. population, respectively. Dermatologists typically rely on visual assessment to diagnose and differentiate the two diseases. While the early symptoms of atopic dermatitis and psoriasis can overlap, long-term treatment plans and overall treatment costs do not. The ability to distinguish these two diseases through precision genomic analysis provides physicians with a valuable asset for clinical decision-making.

Neutral

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

2022-05-03 20:05:00

DermTech, Inc. affirms revenue guidance for the full-year 2022. The company affirmed its full-year 2022 outlook for assay revenue between $22 million and $26 million.

Positive

DermTech, Inc. Announces Publication of New GvHD Clinical Research

2022-04-28 20:30:00

DermTech, Inc. announced the publication of “Noninvasive Genomic Characterization of Patients with Nonsclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease Identified a Novel Gene Signature in Responders to Ruxolitinib Cream,” in Transplantation and Cellular Therapy. Graft versus host disease (GvHD) occurs when transplanted donor immune cells attack the recipient's healthy cells and tissues. Dermatologic manifestations are an important aspect of GvHD, as they are often the earliest organ affected in GvHD and develop in more than half of GvHD patients. While oral ruxolitinib, a JAK1/2 inhibitor, has been approved by the U.S. Food & Drug Administration (FDA) for the treatment of acute and chronic GvHD (cGvHD), this is the first clinical trial evaluating the effectiveness of topical ruxolitinib in cutaneous GvHD patients. Skin samples were non-invasively collected from cutaneous GvHD patients using the DermTech Smart StickerTM and subsequently analyzed by RNA sequencing to investigate the effect of topical ruxolitinib on gene expression in cGvHD. Specifically, the study evaluated the genomic differences between treatment with ruxolitinib cream and vehicle cream and the distinction between patients who responded to treatment and those who did not. Bioinformatic analyses of Smart StickerTM collected skin samples successfully identified 210 differentially expressed genes (DEGs) between topical ruxolitinib and vehicle treatments with primary pathway differences in immune modulation and cell-signaling. Additionally, 383 DEGs were identified which differentiated patients who responded to treatment from those who did not.

Positive

DermTech, Inc. Expands Telehealth Application, DermTech Connect, Across 44 States

2022-04-26 20:30:00

DermTech, Inc. announced the expansion of access to its telehealth application, DermTech Connect, from eight states to 44 states, encompassing approximately 95% of the U.S. population. The mobile app provides improved access to an independent dermatologist, allowing users to choose when to have a mole evaluated by a dermatologist without a trip to a doctor’s office. Patients using DermTech Connect can take a picture of a mole and submit the photo to an independent dermatologist for evaluation for a low-cost consultation fee. A personalized recommendation from the dermatologist can be securely accessed by the patient, typically within 48 hours. If warranted, the dermatologist may order the DermTech Melanoma Test for the patient. The proprietary test uses company’s Smart Stickers™ to non-invasively and painlessly lift skin cells from the surface of the skin, which are then sent to company’s laboratory to be tested for the presence of genomic markers associated with melanoma. A patient sample is self-collected with virtual supervision by qualified, certified personnel. Melanoma is one of the most aggressive and deadliest forms of skin cancer, and early detection is critical to ensure higher survivability rates.

Neutral

DermTech, Inc. - Shareholder/Analyst Call

2022-04-14 20:06:00

Annual General Meeting

Neutral

DermTech, Inc., Annual General Meeting, May 26, 2022

2022-04-14 20:06:00

DermTech, Inc., Annual General Meeting, May 26, 2022, at 13:30 Pacific Standard Time. Agenda: To elect two (2) Class I directors to serve three-year terms expiring in 2025;to ratify the selection of KPMG LLP as the independent registered public accounting firm of DermTech, Inc. for the fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of the Company’s named executive officers;to approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of named executive officers;and to transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.

Neutral

DermTech, Inc. to Report Q1, 2022 Results on May 03, 2022

2022-04-14 20:01:00

DermTech, Inc. announced that they will report Q1, 2022 results on May 03, 2022

Neutral

DermTech, Inc., Q1 2022 Earnings Call, May 03, 2022

2022-04-14 20:01:00

DermTech, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

DermTech, Inc. Presents at 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb-14-2022

2022-01-31 21:01:00

DermTech, Inc. Presents at 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb-14-2022 . Venue: New York, New York, United States.

Neutral

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Neutral

BioIQ, Inc. and DermTech, Inc. Enter into an Agreement to Add Non-Invasive DermTech Melanoma Test to its Health Testing Solution Lineup

2021-12-15 17:23:00

BioIQ, Inc. and DermTech, Inc. announced an agreement to bring increased patient access to precision genomics. The DermTech Melanoma Test is now included in BioIQ's lineup of testing options for employee and member health programs. The program will be available in Florida initially with planned expansion to other states. The agreement between DermTech and BioIQ will allow employers and health plans to drive more convenient access to independent, board-certified dermatologists to assess suspicious skin spots or moles. In addition, the dermatologist can order testing for melanoma using convenient, non-invasive skin sample collection. Members complete an intake process for melanoma risk assessment in the BioIQ Platform, where at-risk patients are flagged for follow up. Through DermTech's telemedicine platform –DermTech ConnectTM, individuals can take photos of a suspicious mole and be connected with a board-certified dermatologist who determines next steps and recommended clinical services. If warranted, the dermatologist can order the DermTech Melanoma Test, beginning with a sample collection kit, which includes the revolutionary DermTech Smart Sticker™, being sent to the patient's home where collection is conducted with support of clinical staff. Diagnosis and further treatment recommendations are based on the dermatologist's medical judgment and individual's test results where applicable.

Positive

DermTech Unveils DermTech Stratum

2021-11-29 21:30:00

DermTech, Inc. announced the expansion and branding of its translational medicine service offering, DermTech Stratum, which utilizes DermTech’s non-invasive technology and precision biomarker approaches to bring heightened precision and personalization to dermatologic disease diagnosis and treatment development. This broadened service offering leverages DermTech’s proprietary platform technology for biomarker analysis of RNA, DNA, protein and microbiome. DermTech’s non-invasive Smart Sticker™ is used to painlessly collect cellular material from the surface of a patient’s skin for precision genomic and proteomic analysis. DermTech Stratum offers the opportunity for research partners and collaborators to non-invasively collect skin samples for analysis to identify biomarkers of disease and subgroups of disease, stratify patients based on genomic and proteomic profiles, enrich for responders in a population and predict and track responses to therapeutic intervention. DermTech Stratum includes expert services such as biomarker identification, new target identification, patient segmentation and stratification, and bioinformatics support. The DermTech Stratum service offering is appropriate for indications where skin is the target or a surrogate target organ and are being used to support drug discovery and development programs focused on cancers and inflammatory diseases in clinical research studies. The DermTech Smart Sticker™ provides a 19mm collection area for lesional and non-lesional samples, collecting 1.5mg of stratum corneum tissue, eliminating the need for surgical biopsies in clinical research studies. Once collected, the sample does not require fixation or refrigeration and preserves genomic and proteomic material from the skin for up to 10 days at room temperature and more than a year when stored at -80 C.

Neutral

DermTech, Inc. Presents at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Nov-16-2021

2021-11-16 11:51:00

DermTech, Inc. Presents at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Nov-16-2021 . Speakers: Michael Howell, Chief Scientific Officer.

Neutral

Hanson Wade Limited, 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Nov 16, 2021 through Nov 18, 2021

2021-11-15 12:30:00

Hanson Wade Limited, 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Nov 16, 2021 through Nov 18, 2021.

Negative

DermTech, Inc. Revised Assay Revenue Guidance for the Full Year of 2021

2021-11-09 21:01:00

DermTech, Inc. announced that due to unforeseen impacts from the Delta variant and hurricane Ida, Management revised its estimated full year 2021 assay revenue to be between $10.5 million and $12.0 million, which still represents a 148% to 183% growth over full year 2020 assay revenue. This compares to previous full year 2021 assay revenue guidance of $11.5 million and $13.5 million.

Neutral

DermTech, Inc. and DermatologistOnCall Enter Agreement to Improve Access to the Dermtech Melanoma Test with Noninvasive

2021-11-08 21:50:00

DermTech, Inc. and DermatologistOnCall announced an agreement to make the DermTech Melanoma Test available through DermatologistOnCall’s telemedicine platform. The millions of patients served through DermatologistOnCall will now have increased access to DermTech’s non-invasive, precision genomics tests for melanoma, the leading cause of skin cancer deaths. The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via the DermTech Smart Sticker™. A patient sample can be collected at home under virtual supervision by a trained DermatologistOnCall clinician. The sample is sent to the DermTech Gene Lab where it is tested for genomic markers linked to melanoma. Using DermatologistOnCall's telemedicine platform is easy. To start the process, a patient uploads photos of a suspicious spot or mole to DermatologistOnCall for review by a U.S. board-certified dermatologist. If the dermatologist determines that a DermTech Melanoma Test is warranted, they will order the Melanoma Test for the patient. The DermTech Adhesive Skin Collection Kit, which contains the DermTech Smart Sticker™, is sent to the patient’s home and the sample collection is conducted under virtual supervision by a DermatologistOnCall clinician. Any diagnosis or further treatment recommendation are based on the individual’s test results and the reviewing dermatologist’s medical judgment.

Neutral

DermTech, Inc. Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 01:30 PM

2021-11-02 20:41:00

DermTech, Inc. Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 01:30 PM.

Neutral

DermTech, Inc. Presents at 12th Annual Craig-Hallum Alpha Select Conference 2021, Nov-16-2021

2021-11-02 20:01:00

DermTech, Inc. Presents at 12th Annual Craig-Hallum Alpha Select Conference 2021, Nov-16-2021 .

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

DermTech, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-26 20:01:00

DermTech, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

DermTech, Inc. to Report Q3, 2021 Results on Nov 09, 2021

2021-10-26 20:01:00

DermTech, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

DermTech, Inc. Presents at MedTech Innovation Forum 2021, Oct-28-2021 11:20 AM

2021-10-25 13:48:00

DermTech, Inc. Presents at MedTech Innovation Forum 2021, Oct-28-2021 11:20 AM. Venue: AV Irvine, Irvine, California, United States. Speakers: Michael Howell, Chief Scientific Officer.

Neutral

OCTANe LLC, MedTech Innovation Forum 2021, Oct 28, 2021 through Oct 29, 2021

2021-10-25 11:30:00

OCTANe LLC, MedTech Innovation Forum 2021, Oct 28, 2021 through Oct 29, 2021. Venue: AV Irvine, Irvine, California, United States.

Neutral

Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021

2021-10-14 22:02:00

Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021.

Negative

DermTech Announces Appointment of Nathalie Gerschtein Keraudy to Its Board of Directors

2021-10-04 20:01:00

DermTech, Inc. announced the appointment of Nathalie Gerschtein Keraudy, President of the Consumer Products Division of L’Oréal, to its board of directors. Nathalie’s experience includes 20 years at L’Oréal in roles of progressive leadership responsibility across Europe, Asia, and America. In Nathalie’s current role as president of the largest division in L’Oréal Group’s top subsidiary, Nathalie is responsible for accelerating growth, innovation, and sustainable practices across its mass market portfolio of brands and product categories, from skin care and makeup to hair care and color.

Positive

DermTech, Inc Leases Approximately 96,000 Square Feet of Class A Space At the Del Mar Corporate Centre

2021-09-22 15:30:00

Cushman & Wakefield announced that DermTech, Inc. has leased approximately 96,000 square feet of Class A space at the Del Mar Corporate Centre (DMCC) for its new corporate headquarters in Del Mar Heights (San Diego), California. The building will also be the site of the company’s laboratory (the “DermTech Gene Lab”) where DermTech will among other things, process its DermTech Melanoma Test to aid in the early detection of melanoma. Owned by Kilroy Realty, DMCC is a three-building, Class A campus featuring well-appointed design, beautiful common areas and outdoor lounges, and a prime, prominent presence. DMCC is surrounded by world-class shopping and dining, and is near many of San Diego’s top neighborhoods. The campus also has excellent visibility and accessibility from Interstate 5. Cushman & Wakefield’s David Odmark represented DermTech and Cushman & Wakefield’s Brett Ward, Brian Starck and Michael Cassolato represented Kilroy Realty in the transaction. DermTech’s new headquarters will be located at 12340 El Camino Real and will undergo a significant transformation that will include conversion of office space to life sciences laboratory space.

Neutral

DermTech, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-22-2021 04:35 PM

2021-09-08 20:01:00

DermTech, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-22-2021 04:35 PM.

Neutral

Craig-Hallum Capital Group LLC, 12th Annual Craig-Hallum Alpha Select Conference 2021, Nov 16, 2021

2021-09-08 08:33:00

Craig-Hallum Capital Group LLC, 12th Annual Craig-Hallum Alpha Select Conference 2021, Nov 16, 2021.

Neutral

DermTech, Inc. Presents at 2021 Florida Association of Health Plans Annual Conference, Nov-14-2021

2021-09-05 04:14:00

DermTech, Inc. Presents at 2021 Florida Association of Health Plans Annual Conference, Nov-14-2021 .

Neutral

Florida Association of Health Plans, 2021 Florida Association of Health Plans Annual Conference, Nov 14, 2021 through Nov 16, 2021

2021-09-02 21:59:00

Florida Association of Health Plans, 2021 Florida Association of Health Plans Annual Conference, Nov 14, 2021 through Nov 16, 2021.

Neutral

DermTech, Inc. Provides Financial Guidance for the Full Year 2021

2021-08-04 20:01:00

DermTech, Inc. provided financial guidance for the full year 2021. Management estimates that full year 2021 assay revenue will be between $11.5 million and $13.5 million, which represents 171% to 218% growth over full year 2020 assay revenue and considers the uncertainly regarding the pandemic.

Neutral

DermTech, Inc. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021

2021-07-31 04:07:00

DermTech, Inc. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021 .

Neutral

Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021

2021-07-30 21:59:00

Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021.

Negative

DermTech Names Monica Tellado to Its Board of Directors

2021-07-24 15:59:00

DermTech reported the appointment of Monica Tellado, Senior Vice President, Finance at Gilead Sciences to its Board of Directors. Tellado's experience includes 18 years at Gilead Sciences, in roles of progressive leadership responsibility up to and including her current role as Senior Vice President Finance.

Neutral

DermTech, Inc. to Report Q2, 2021 Results on Aug 04, 2021

2021-07-21 20:30:00

DermTech, Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

DermTech, Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-21 20:30:00

DermTech, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Positive

DermTech, Inc. Announces Expansion Plans to Support the Company’s Continued Growth in San Diego

2021-07-21 20:05:00

DermTech, Inc. announced expansion plans to support the Company’s continued growth in San Diego, with the lease of a building owned by Kilroy Realty. The 95,997 square-foot building will become DermTech’s new corporate headquarters and the site of its laboratory (the “DermTech Gene Lab”) where DermTech will among other things, process its DermTech Melanoma Test to aid in the early detection of melanoma. The property at 12340 El Camino Real, will undergo a significant transformation that will include conversion of approximately 30,000 square feet of office space to life science laboratory space, and will become available to the Company in four phases. The first portion of the new building is slated to open in the next couple of months and will include office space for the DermTech team. The next portion of the building is slated to open throughout 2022 and will offer a brand-new, space for the DermTech Gene Lab, further expanding the Company’s laboratory capacity to support expected growth in commercial diagnostic test volume. This phase will also include separate dedicated laboratory space to enhance the Company’s research and development capabilities, as well as additional office space to support expected growth in commercial and administrative teams. The lease has a term of 126 months, with two options to extend the lease term for 5 additional years each. DermTech leased the new building from Los Angeles-based developer Kilroy Realty, who is working to help further the growing regional demand for space among biotech companies.

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Neutral

Dermtech, Inc., Enters into an Office Lease, or the Lease, with Kilroy Realty, L.P

2021-07-07 21:01:00

On July 1, 2021, DermTech, Inc., or the Company, entered into an Office Lease, or the Lease, with Kilroy Realty, L.P., or the Landlord, with respect to an aggregate of 95,997 rentable square feet consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130, or the Entire Premises. The Entire Premises covered by the Lease will serve as the Company’s new principal office. The Lease provides that the Landlord will cause the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Lease is ten (10) years and six (6) months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Lease, or the Lease Commencement Date. The Company has the option to extend the term of the Lease for two (2) additional five (5) year periods, subject to the terms of the Lease. As the Landlord tenders possession of each portion of the Entire Premises for which the applicable improvements required by the Lease are substantially complete, the Company will be obligated to make monthly payments of base rent with respect to such portion of the Entire Premises as set forth on Schedule 1 to the Lease. In the event the Company exercises its option to extend the Lease term, the Lease provides for monthly rent payments during the additional five (5) year periods at the then-current market rent as determined in accordance with the Lease. In addition to rent, the Lease requires the Company to pay additional rent amounts for taxes, insurance, maintenance and other expenses. Concurrently with the execution of the Lease, the Company delivered to the Landlord a security deposit in the amount of $3,023,906 in the form of a letter of credit. Such Letter of Credit shall be reduced to $2,015,937 on the third anniversary of the Lease Commencement Date and reduced to $1,007,969 on the fifth anniversary of the Lease Commencement Date.Pursuant to the Lease, the Company also has a right of first refusal to lease additional space in another building owned by the Landlord and located at 12390 El Camino Real, San Diego, California on certain terms and conditions set forth in the Lease. The Lease contains customary events of default that, among other things, entitle the Landlord to terminate the Lease and recover from the Company the worth of any unpaid rent for the remainder of the term of Lease in excess of such rental loss that the Company proves could have been reasonably avoided by Landlord, plus certain additional costs and expenses arising from the termination. The specified events of default include, among other things, nonpayment of rent or other amounts required to be paid by the Company under the Lease and insolvency events.

Negative

Scott Pancoast Resigns from the Board of Directors of DermTech, Inc

2021-07-02 21:01:00

On June 30, 2021, DermTech, Inc. and Scott Pancoast, a former director of the Company, voluntarily resigned from the Board of Directors of the Company, or the Board. Mr. Pancoast and the Company entered into a letter agreement, or the Agreement, in connection with Mr. Pancoast’s resignation, which memorializes the terms of Mr. Pancoast’s resignation from the Company.

Fundamental Summary

DermTech published concerning results on 2022-03-10. Their growth, value, and income factors performance indicate that company management are not executing well their business plan. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. Therefore, we assessed them with a rating of 47 and a UNDERPERFORM recommendation.

DermTech reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.2 million compared to USD 0.334 million a year ago. Revenue was USD 3.72 million compared to USD 2.52 million a year ago. Net loss was USD 30.11 million compared to USD 15.07 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 0.55 a year ago.

Business Description

DermTech, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech is headquartered in La Jolla, California.

Sector Overview

DermTech is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. DermTech's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 248.3 -8.0% 72
Liabilities 18.6 3.5% 76
Price to Book 2.0 -45.9% 43
Cash & Equivalents 176.9 -13.3% 52
Equity 229.7 -8.8% 51
EBITDA -74.2 -31.0% 48
Total Revenues 11.8 9.7% 49
Parameter Value Change Score
Return on Equity -53.7 -32.3% 78
Net Cashflow 155.7 -19.1% 60
Capital Expenditure -2.7 -41.6% 45
Asset Turnover 0.1 12.7% 86
Free Cashflow -2.2 -23.1% 51

* All values are TTM

The below chart reflects DermTech's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While DermTech's peer average final assessment score stands on 57.0, DermTech's score is 47.

  •  DMTK
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 1 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 2 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 3 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 4 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 6 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 7 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 8 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 9 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 10 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 11 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 12 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 13 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 14 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 15 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. DermTech's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), DermTech's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 5.52
52W Low 4.39
52W High 43.53
5D MA 5.97
50D MA 7.19
200D MA 16.72
MACD -0.46
RSI 26.17
STOCH 50.67

Balance Sheet Analysis

Several numbers from DermTech's current balance sheet were concerning, in two areas in particular: Book Value Factors and Equity. DermTech publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 2.0 and represents -45.9% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 23.0%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 43. Also, DermTech published concerning equity metrics for this filing. In the current report, equity stood at 229.7, which represents a -8.8% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.7%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Its equity movement component, therefore, received a grade of 51. On the other hand, Liabilities, jumped out as looking rather positive. In terms of liabilities, DermTech published good numbers. Their reported liabilities were 18.6, representing a 3.5% change from the previous report. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 76. The company's balance sheet, Therefore, earned a score of 56.

Parameter Value Change Score
Assets 248.3 -8.0% 72
Liabilities 18.6 3.5% 76
Price to Book 2.0 -45.9% 43
Cash & Equivalents 176.9 -13.3% 52
Equity 229.7 -8.8% 51
* All values are TTM

The below chart describes DermTech's performance as reflected on its balance sheet with respect to its peers. While DermTech received a balance sheet score of 56, the average of its peers stands on 65.0.

  •  DMTK
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 1 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 2 1
Vericel Corporation 1.1B 51 65 56 53 61 57 3 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 4 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 6 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 7 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 8 1
Immatics N.V. 538.7M 56 70 84 95 73 76 9 1
Agenus Inc. 520.5M 73 62 37 55 60 54 10 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 11 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 12 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 13 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 14 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 15 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

DermTech's income statement report highlighted several concerning metrics. DermTech's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -74.2, which represents a -31.0% change from the last period. This metric might have a 23.8 percent impact on companies in the same industry and with the same market capitalization. DermTech appears to be headed in the wrong direction in terms of EBITDA momentum, likely due to insufficient capital controls and a weaker than expected overall financial performance. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 48. Also, DermTech's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 12.9 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. As a result, their revenue efficiency earned a score of 49. However, one encouraging metric, Return Factors, stood out. DermTech's reported return on equity (ROE) ratio was -53.7, representing a change of -32.3%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 78. Therefore, it received a cautionary score of 52.

Parameter Value Change Score
EBITDA -74.2 -31.0% 48
Total Revenues 11.8 9.7% 49
Return on Equity -53.7 -32.3% 78
* All values are TTM

The below chart describes DermTech's performance as reflected on its income statement with respect to its peers. While DermTech received a income statement score of 52 , the average of its peers stands on 55.0.

  •  DMTK
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 1 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 2 1
Vericel Corporation 1.1B 76 44 82 56 3 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 4 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 6 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 7 1
CTI BioPharma Corp. 603.6M 84 50 62 59 8 1
Immatics N.V. 538.7M 37 93 53 77 9 1
Agenus Inc. 520.5M 57 83 45 74 10 1
Vaxart, Inc. 440.0M 99 51 72 68 11 1
MiMedx Group, Inc. 391.5M 87 43 83 59 12 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 13 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 14 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 15 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

DermTech's recently published cash flow conveys disappointing growth, particularly with respect to Capital Expenditure and Free Cash flow metrics. DermTech's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -2.7, which represents a -41.6% change from the last period. They appears to be headed in the wrong direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Its CapEx movement, therefore, received a grade of 45. Also, DermTech did a poor job related to generating and maintaining strong free cash flow this period, which stood at -2.2, representing a -23.1% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.8%. Their free cash flow situation is more concerning relative to their peers and competitors. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 51. On the other hand, Asset Turnover, jumped out as looking rather positive. DermTech is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.1, representing a 12.7% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 3.2%. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Correspondingly, their asset turnover movement received a grade of 86. Therefore, the company's cash flow earned a grade of 58.

Parameter Value Change Score
Net Cashflow 155.7 -19.1% 60
Capital Expenditure -2.7 -41.6% 45
Asset Turnover 0.1 12.7% 86
Free Cashflow -2.2 -23.1% 51
* All values are TTM

The below chart describes DermTech's performance as reflected on its cash flow with respect to its peers. While DermTech received a cash flow score of 58, the average of its peers stands on 60.0.

  •  DMTK
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 1 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 2 1
Vericel Corporation 1.1B 64 46 59 73 65 3 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 4 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 6 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 7 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 8 1
Immatics N.V. 538.7M 82 95 56 99 86 9 1
Agenus Inc. 520.5M 57 43 52 77 58 10 1
Vaxart, Inc. 440.0M 72 56 53 38 65 11 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 12 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 13 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 14 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 15 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.